Anthony A. Attama

9.7k citations

229 papers · 4.5k indexed · 1 hit paper · h-index 36

Pharmaceutical Science top 0.05%
Molecular Biology top 10%
Food Science top 1%
Biomaterials top 2%
Public Health, Environmental and Occupational Health top 5%

Co-authors: Christel C. Müller‐Goymann Franklin Chimaobi Kenechukwu Petra O. Nnamani Philip F. Builders A J Wakefield R E Pounder Stephan Reichl Chukwuebuka Emmanuel Umeyor
Topics: Advanced Drug Delivery Systems (84 papers)Advancements in Transdermal Drug Delivery (71 papers)Drug Solubulity and Delivery Systems (58 papers)
Cited by: Pharmaceutical Science Food Science Biomaterials
Journals: SHILAP Revista de lepidopterologíaGastroenterology Gut
Partner nations: Nigeria United Kingdom Germany

In The Last Decade

Anthony A. Attama

222 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases

2023 193 citations Adaeze Linda Onugwu, Chinekwu Sherridan Nwagwu et al. Journal of Controlled Release profile →

Peers

Countries citing papers authored by Anthony A. Attama

Since Specialization

Citations

This map shows the geographic impact of Anthony A. Attama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony A. Attama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony A. Attama more than expected).

Fields of papers citing papers by Anthony A. Attama

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anthony A. Attama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony A. Attama. The network helps show where Anthony A. Attama may publish in the future.

Co-authorship network of co-authors of Anthony A. Attama

This figure shows the co-authorship network connecting the top 25 collaborators of Anthony A. Attama. A scholar is included among the top collaborators of Anthony A. Attama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anthony A. Attama. Anthony A. Attama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ocimum Gratissimum essential oil: A review of extraction methods, phytochemical constituents, pharmacological uses and formulation approaches 2023 ·(unknown),(unknown),(unknown),Anthony A. Attama	1
2	Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseasesbreakdown → 2023 ·Journal of Controlled Release ·Adaeze Linda Onugwu,Chinekwu Sherridan Nwagwu,(unknown),Adaeze Chidiebere Echezona,Chinazom Precious Agbo,Stella Amarachi Ihim,(unknown),Petra O. Nnamani,Anthony A. Attama,Vitaliy V. Khutoryanskiy	193
3	Nanotheranostics: Platforms, Current Applications, and Mechanisms of Targeting in Breast and Prostate Cancers 2023 ·SHILAP Revista de lepidopterología ·Paul A. Akpa,(unknown),(unknown),(unknown),(unknown),Chukwuemeka S. Nworu,Paul M. Ejikeme,(unknown),Anthony A. Attama,Peter A. Akah	7
4	Lipid-based Nanoparticles (LNP) Structures used for Drug Delivery andTargeting: Clinical Trials and Patents 2023 ·Nanoscience &amp Nanotechnology-Asia ·Salome Amarachi Chime,Anthony A. Attama	2
5	Evaluating some Essential Oils-Based and Coconut Oil Nanoemulgels for the Management of Rheumatoid Arthritis 2022 ·Letters in Applied NanoBioScience ·(unknown),(unknown),(unknown),Chukwuebuka Emmanuel Umeyor,(unknown),(unknown),Anthony A. Attama,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	5
6	Novel Bos indicus Fat-Based Nanoparticulate Lipospheres of Miconazole Nitrate as Enhanced Mucoadhesive Therapy for Oral Candidiasis 2022 ·Biointerface Research in Applied Chemistry ·Franklin Chimaobi Kenechukwu,(unknown),Mumuni A. Momoh,(unknown),Anthony A. Attama,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	4
7	Formulation Design and Preclinical Evaluations of Surface Modified Lipid Nanoparticles-Coupled Gel Encapsulating Dihydroartemisinin for Treatment of Localized Inflammation 2021 ·Letters in Applied NanoBioScience ·Chukwuebuka Emmanuel Umeyor,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Anthony A. Attama,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	4
8	Optimized Development, Characterization and Antimicrobial Evaluation of Bioactive Prodigiosin Potentials from Cephalosporin Resistant Serratia marcescens 2020 ·(unknown),(unknown),Anthony A. Attama,Emmanuel C. Ibezim,(unknown),(unknown)	1
9	Evaluation of the Properties of Encapsulated Stavudine Microparticulate Lipid-based Drug Delivery System in Immunocompromised Wistar Rats 2020 ·Current HIV Research ·Salome Amarachi Chime,(unknown),Anthony A. Attama	3
10	Anti-Inflammatory and Gastroprotective Properties of Aspirin - Entrapped Solid Lipid Microparticles 2020 ·Recent Patents on Inflammation & Allergy Drug Discovery ·Salome Amarachi Chime,Paul A. Akpa,(unknown),Anthony A. Attama	6
11	Physicochemical and safety characteristics of novel microstructured lipid-based drug delivery system encapsulating miconazole nitrate 2017 ·Franklin Chimaobi Kenechukwu,Anthony A. Attama,Emmanuel C. Ibezim,(unknown),(unknown)	2
12	Formulation, in vitro and in vivo evaluation of halofantrine-loaded solid lipid microparticles 2014 ·Pharmaceutical Development and Technology ·(unknown),Franklin Chimaobi Kenechukwu,(unknown),(unknown),Anthony A. Attama	7
13	The combined antibacterial activity of face cleansing agents and Psidium guajava leaf extract on methicillin-resistant Staphylococcus aureus. 2014 ·International Journal of Agriculture and Biosciences ·(unknown),(unknown),(unknown),Charles Okechukwu Esimone,Anthony A. Attama	1
14	Recent advances in particulate anti-malarial drug delivery systems: A review 2013 ·International Journal of Phytomedicine ·Chukwuebuka Emmanuel Umeyor,Franklin Chimaobi Kenechukwu,(unknown),Salome Amarachi Chime,(unknown),Anthony A. Attama	11
15	Pharmacokinetics and biodistribution of zidovudine loaded in a solidified reverse micellar delivery system. 2013 ·International Journal of Phytomedicine ·(unknown),(unknown),Franklin Chimaobi Kenechukwu,Mumuni A. Momoh,Anthony A. Attama,(unknown)	4
16	Spectrophotometric Determination of Lamivudine Using Chloranilic Acid and 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) 2011 ·American Journal of Analytical Chemistry ·(unknown),P. O. Ukoha,Anthony A. Attama	15
17	Piroxicam-Loaded P90gylated Tallow Fat-Based Solid Lipid Microparticles: Characterization and in Vivo Evaluation 2010 ·Petra O. Nnamani,(unknown),Anthony A. Attama,(unknown)	1
18	Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children (Retraction of vol 351, pg 637, 1998) 2004 ·UCL Discovery (University College London) ·S. H. Murch,Anthony A. Attama,(unknown),Muhammad Akbar Malik,Mark Berelowitz,(unknown),(unknown),A. R. Valentine,Sarah L. Davies,(unknown)	2
19	Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children (Retracted article. See vol 375, pg 445, 2010) 1998 ·UCL Discovery (University College London) ·AJ Wakefield,S. H. Murch,Anthony A. Attama,J. C. Linnell,(unknown),M.M. Malik,Mark Berelowitz,(unknown),(unknown),Peter Harvey,A. R. Valentine,(unknown),(unknown)	51
20	Azure B-RNA changes in the adrenal and cerebral cortex of rats exposed to intense noise. 1973 ·PubMed ·Anthony A. Attama	9

About Anthony A. Attama

Anthony A. Attama is a scholar working on Pharmaceutical Science, Drug Discovery and Food Science, having authored 229 papers that have together received 4.5k indexed citations. Recurring topics across this work include Advanced Drug Delivery Systems (84 papers), Advancements in Transdermal Drug Delivery (71 papers) and Drug Solubulity and Delivery Systems (58 papers). The work is most often cited by research in Pharmaceutical Science (2.0k citations), Food Science (797 citations) and Biomaterials (475 citations). Anthony A. Attama has collaborated with scholars based in Nigeria, United Kingdom and Germany. Frequent co-authors include Christel C. Müller‐Goymann, Franklin Chimaobi Kenechukwu, Petra O. Nnamani, Philip F. Builders, A J Wakefield, R E Pounder, Stephan Reichl, Chukwuebuka Emmanuel Umeyor, Mumuni A. Momoh and Amar P. Dhillon. Their work appears in journals such as SHILAP Revista de lepidopterología, Gastroenterology and Gut.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact